RPT

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

Retrieved on: 
Tuesday, November 22, 2022
Health, Platform, RPT, Immunotherapy, Drug delivery, Therapy, Liver, Liver disease, Partnership, FDA, Pancreas, Patient, Uveal melanoma, Immune system, PET, CD8, Phase II, Medical imaging, Pharmaceutical industry

Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery (PEDD) method for intravascular delivery of its investigational SD-101 compound.

Key Points: 
  • Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery (PEDD) method for intravascular delivery of its investigational SD-101 compound.
  • Our agreement with TriSalus highlights our expanding partnership network and showcases the increasing adoption of our CD8 ImmunoPET technology."
  • CD8 ImmunoPET is an 89Zr-labelled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging of CD8+ T cells.
  • TriSalusLife Sciences is anoncology therapeutics company integrating immunotherapy withdisruptivedelivery technology to transform the treatment paradigm for patients with liver andpancreatictumors.

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

Retrieved on: 
Tuesday, November 22, 2022
Health, Platform, RPT, Immunotherapy, Drug delivery, Therapy, Liver, Liver disease, Partnership, FDA, Pancreas, Patient, Uveal melanoma, Immune system, PET, CD8, Phase II, Medical imaging, Pharmaceutical industry

Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery (PEDD) method for intravascular delivery of its investigational SD-101 compound.

Key Points: 
  • Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery (PEDD) method for intravascular delivery of its investigational SD-101 compound.
  • Our agreement with TriSalus highlights our expanding partnership network and showcases the increasing adoption of our CD8 ImmunoPET technology."
  • CD8 ImmunoPET is an 89Zr-labelled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging of CD8+ T cells.
  • TriSalusLife Sciences is anoncology therapeutics company integrating immunotherapy withdisruptivedelivery technology to transform the treatment paradigm for patients with liver andpancreatictumors.

ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology

Retrieved on: 
Tuesday, November 15, 2022
Health, RPT, Immunotherapy, Therapy, Autoimmune disease, Hope, Cancer, Biotechnology, Patient, Degenerative disease, CEO, Clinical trial, PET, CD8, Science, Pharmaceutical industry

Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPETto DynamiCure Biotechnology for use in its clinical trial.

Key Points: 
  • Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPETto DynamiCure Biotechnology for use in its clinical trial.
  • Commenting on the announcement, Ian Wilson, CEO of ImaginAb, said: "We are delighted that DynamiCure Biotechnology will be using our CD8 ImmunoPETtechnology in its clinical trial.
  • This license and supply agreement allows our proprietary investigational technology to be used in additional immuno-oncology clinical trials with the hope that it assists DynamiCure Biotechnology with the development of their novel therapeutic products.
  • CD8 ImmunoPETis a 89Zr-labelled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging of CD8+ T cells.

ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology

Retrieved on: 
Tuesday, November 15, 2022
Health, RPT, Immunotherapy, Therapy, Autoimmune disease, Hope, Cancer, Biotechnology, Patient, Degenerative disease, CEO, Clinical trial, PET, CD8, Science, Pharmaceutical industry

Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPETto DynamiCure Biotechnology for use in its clinical trial.

Key Points: 
  • Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPETto DynamiCure Biotechnology for use in its clinical trial.
  • Commenting on the announcement, Ian Wilson, CEO of ImaginAb, said: "We are delighted that DynamiCure Biotechnology will be using our CD8 ImmunoPETtechnology in its clinical trial.
  • This license and supply agreement allows our proprietary investigational technology to be used in additional immuno-oncology clinical trials with the hope that it assists DynamiCure Biotechnology with the development of their novel therapeutic products.
  • CD8 ImmunoPETis a 89Zr-labelled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging of CD8+ T cells.

Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program

Retrieved on: 
Thursday, November 10, 2022
Research, Clinical Trials, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Tumor microenvironment, Collagen, PET, Immunotherapy, Health, RPT, Neoplasm, Technology, CD8, DDR1, Therapy, Doctor of Philosophy, Cancer, Phenotype, Biomarker, Drug development, Clinical trial, Cell, Patient, Immune system, TME, Data, Phase II, Pharmaceutical industry, Medical imaging, Parthenon

This knowledge will help us design a clinical strategy to focus on those patients who will benefit the most from treatment with PRTH-101.

Key Points: 
  • This knowledge will help us design a clinical strategy to focus on those patients who will benefit the most from treatment with PRTH-101.
  • Under the terms of the agreement, ImaginAb will supply clinical doses of its investigational CD8 ImmunoPET technology to Parthenon Therapeutics for use in the clinical development of PRTH-101 at clinical trial sites across the United States.
  • ImaginAb is actively investing in the clinical and global supply chain development of CD8 ImmunoPET agent to provide simple turnkey access to its novel technology for use in clinical research and development.
  • Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).

Badger Infrastructure Solutions Ltd. Announces 2022 Third Quarter Results

Retrieved on: 
Thursday, November 3, 2022
Loosen' Control, Company, Electricity, Growth, Time, Sale, Board, Soil, Safety, Webcast, Legislation, EBITDA, Natural gas, Vaccination, RPT, Solution, COVID-19, Investment, Marketing, Sustainability Accounting Standards Board, Telecommunication, Sewage, Tax, Weather, Consolidated, Business, TSX, Adjustment, Health, Retirement, Depreciation, SEDAR, MRP, Program, Communication, Water, Risk management, Holding company, Retail, Renewable energy, Environmental remediation, Audit, Bookkeeping, Public utility, Bank, Badger

(2)See Share Capital in the Companys 2021 annual MD&A and third quarter 2022 MD&A for additional details.

Key Points: 
  • (2)See Share Capital in the Companys 2021 annual MD&A and third quarter 2022 MD&A for additional details.
  • About Badger Infrastructure Solutions Ltd.
    Badger Infrastructure Solutions Ltd. (TSX:BDGI) is North Americas largest provider of non-destructive excavating services.
  • The Badger Airvac complements the Badger Hydrovac, and both are designed and manufactured by Badger.
  • Badgers third quarter 2022 Managements Discussion and Analysis and 2022 Unaudited Interim Condensed Consolidated Financial Statements, along with all previous public filings of Badger Infrastructure Solutions Ltd. may be found on SEDAR at www.sedar.com.

RPT Realty Declares Fourth Quarter 2022 Common and Preferred Share Dividends

Retrieved on: 
Thursday, October 27, 2022
Trustee, Board, Board of directors, Company, NYSE, RPT Realty, New, RPT, GLOBE, Series, REIT, Holding company, Reinsurance, Security (finance)

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- RPT Realty (NYSE:RPT) (RPT or the Company) announced today that its Board of Trustees declared a fourth quarter 2022 regular cash dividend of $0.13 per common share.

Key Points: 
  • NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- RPT Realty (NYSE:RPT) (RPT or the Company) announced today that its Board of Trustees declared a fourth quarter 2022 regular cash dividend of $0.13 per common share.
  • The Board of Trustees also approved a fourth quarter 2022 Series D convertible preferred share dividend of $0.90625 per share.
  • The dividends for the period October 1, 2022 through December 31, 2022 are payable on January 3, 2023 for shareholders of record on December 20, 2022.
  • The common shares of the Company, par value $0.01 per share are listed and traded on the NYSE under the ticker symbol RPT.

RPT Realty Awarded Green Star For Excellence In ESG Performance

Retrieved on: 
Monday, October 17, 2022
Benchmark, Biophysical environment, Element, New, Growth, RPT, Management Component Transport Protocol, ESG, NYSE, Investment, REIT, Senior, Green star, Social, Corporate governance, Company, Corporate responsibility, Â, RPT Realty, CEO, GLOBE, Common Ground, Social Security Government Pension Offset, Management

GRESB is a mission-driven and industry-led organization providing standardized and validated ESG data to financial markets.

Key Points: 
  • GRESB is a mission-driven and industry-led organization providing standardized and validated ESG data to financial markets.
  • GRESB awarded RPT a Green Star for excellence in ESG performance.
  • RPT has become a champion for ESG excellence, with nearly perfect scores on the S and G elements of GRESB, and an E score that is approximately 8% higher than the benchmark average.
  • RPT Realty owns and operates a national portfolio of open-air shopping destinations principally located in top U.S. markets.

ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia

Retrieved on: 
Monday, October 17, 2022
CD8, Disease, Medicine, Master service agreement, Life, Diagnosis, RPT, History, Technology, Company, Neurology, Health, Immunotherapy, PET, Radiopharmaceutical, Pharmaceutical industry, Management, Medical imaging

INGLEWOOD, Calif., Oct. 17, 2022 /PRNewswire/ -- ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, is pleased to announce the completion of a Master Services Agreement with Cyclotek, a leading radiopharmaceutical manufacturer in Australia and New Zealand, for the commercial manufacturing and distribution of its investigational CD8 ImmunoPET agent in Australia.

Key Points: 
  • INGLEWOOD, Calif., Oct. 17, 2022 /PRNewswire/ -- ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, is pleased to announce the completion of a Master Services Agreement with Cyclotek, a leading radiopharmaceutical manufacturer in Australia and New Zealand, for the commercial manufacturing and distribution of its investigational CD8 ImmunoPET agent in Australia.
  • Ian Wilson, Chief Executive Officer of ImaginAb, said:
    "ImaginAb is very pleased to be partnering with Cyclotek, a well-established and reliable supplier of quality PET radiopharmaceuticals in Australia as we continue to strengthen and expand our CD8 ImmunoPET manufacture network in Australia and across the globe.
  • This agreement is part of our continued thrust to establish a worldwide leading manufacturing distribution network for our imaging agent, as we progress towards our goal to gain regulatory approval of our technology in multiple geographies."
  • As a leading radiopharmaceutical manufacturer in Australia and New Zealand, Cyclotek's mission is to improve patient outcomes with accessible targeted radiopharmaceuticals.

ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia

Retrieved on: 
Monday, October 17, 2022
CD8, Disease, Medicine, Master service agreement, Life, Diagnosis, RPT, History, Technology, Company, Neurology, Health, Immunotherapy, PET, Radiopharmaceutical, Pharmaceutical industry, Management, Medical imaging

INGLEWOOD, Calif., Oct. 17, 2022 /PRNewswire/ -- ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, is pleased to announce the completion of a Master Services Agreement with Cyclotek, a leading radiopharmaceutical manufacturer in Australia and New Zealand, for the commercial manufacturing and distribution of its investigational CD8 ImmunoPET agent in Australia.

Key Points: 
  • INGLEWOOD, Calif., Oct. 17, 2022 /PRNewswire/ -- ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, is pleased to announce the completion of a Master Services Agreement with Cyclotek, a leading radiopharmaceutical manufacturer in Australia and New Zealand, for the commercial manufacturing and distribution of its investigational CD8 ImmunoPET agent in Australia.
  • Ian Wilson, Chief Executive Officer of ImaginAb, said:
    "ImaginAb is very pleased to be partnering with Cyclotek, a well-established and reliable supplier of quality PET radiopharmaceuticals in Australia as we continue to strengthen and expand our CD8 ImmunoPET manufacture network in Australia and across the globe.
  • This agreement is part of our continued thrust to establish a worldwide leading manufacturing distribution network for our imaging agent, as we progress towards our goal to gain regulatory approval of our technology in multiple geographies."
  • As a leading radiopharmaceutical manufacturer in Australia and New Zealand, Cyclotek's mission is to improve patient outcomes with accessible targeted radiopharmaceuticals.